Thymosin beta-4 research and TB-500
The wound result is striking. The strength result is disappointing. Both deserve a place in the file.
Thymosin beta-4 and cell movement
The biology begins with a practical problem inside a cell: how to hold actin in reserve while continually rebuilding the strands that give the cell shape. Full-length thymosin beta-4 binds a single actin molecule in a 1:1 complex. Irobi and colleagues examined a gelsolin-domain-1–thymosin-beta-4 hybrid using X-ray crystallography at 2 Å, resolving how the complex caps the actin monomer’s ends and prevents assembly into a strand.
TB-500 contains the LKKTETQ actin-binding motif. Full-length thymosin beta-4 also has other regions and can yield Ac-SDKP, a separate fragment associated with anti-fibrotic and angiogenic activity; the parent protein has a broader repertoire. TB-500 cannot supply that N-terminal cleavage product.
I grant the shared sequence a plausible biological starting point. Assigning every full-length result to the isolated fragment goes well beyond that starting point.
TB-500 benefits and the wound studies
Malinda and colleagues tested full-length thymosin beta-4 in rats with full-thickness wounds. Compared with saline, re-epithelialization increased by 42% at 4 days and up to 61% at 7 days. Wound contraction increased by ≥11% by day 7, with more collagen deposition and angiogenesis, the formation of blood vessels. In cell-culture migration assays, as little as 10 pg stimulated keratinocytes, the skin-surface cells, with a 2–3-fold effect.
The small laboratory quantity is impressive. A claim about healing a person’s tendon crosses differences in material, tissue and subjects that the experiment leaves untested. The full-length literature includes an animal ligament-healing result in the tissue-repair review; human tendon and ligament benefit for the fragment remains unproved.
Muscle fibres and strength
In dystrophin-deficient mice, chronic full-length thymosin beta-4 produced more regenerating skeletal-muscle fibres, with no significant improvement in muscle strength or systolic cardiac function. Skeletal and cardiac fibrosis stayed elevated. That outcome makes the recovery story considerably harder to compress into a slogan.
“Regeneration” sounded more conclusive to me before this paper. The new fibres were a real observation, yet the functional outcomes disappointed. This mouse model also has its own disease context; it supplies neither a result for ordinary exercise recovery nor a human TB-500 result.
Stroke and recent delivery research
In rats after embolic stroke, full-length thymosin beta-4 improved neurological function in the earlier study. The later dose-response experiment found benefit at 2 and 12 mg/kg, with no significant benefit at 18 mg/kg. Those quantities describe an animal experiment. The dosage file gives the setting.
Recent work widens the experimental questions. A 2024 animal and cell study implicated pro-resolving pathways in thymosin beta-4’s effects, meaning processes involved in bringing inflammation to an end. In a 2025 rodent wound study, a thymosin-beta-4–exosome-loaded hydrogel improved vascularized repair. The material combined a delivery system with hemostatic and antibacterial properties. It would take a separate experiment to assign that combined result to free TB-500.
I would interrogate the delivery system alongside the peptide: how much of a result survives when the material and its surroundings change? The 2026 sports-medicine review describes promising animal findings alongside scarce rigorous human safety data and potential for serious harm. That is a fair place to leave the clinical case open.